A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (NCT02734771)
🩺 Plain-English Summary (8th-Grade Level)
This is a study incorporating brentuximab vedotin and dose attenuated rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) into initial therapy for elderly patients with DLBCL. Vincristine will be omitted from the standard R-CHOP regimen given the overlapping toxicities with brentuximab vedotin.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (10 items) and avoid the listed exclusions (18 items).
Location: James P. Wilmot Cancer Institute, University of Rochester Medical Center — Rochester, New York
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Patient has a platelet count of ≤50,000/mm3 within 14 days before enrollment.
- Patient has an absolute neutrophil count of \< 1,000/mm3 within 14 days before enrollment.
- Patient has a calculated or measured creatinine clearance of \<30 mL/minute within 14 days before enrollment.
- Patient is receiving peritoneal dialysis or hemodialysis
- Patient has ≥Grade 2 peripheral neuropathy within 14 days before enrollment.
- Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
- New York Heart Association class III heart failure or ejection fraction of less than 30% on echocardiogram or Multi Gated Acquisition Scan (MUGA)
- Patient has received other investigational drugs with 14 days before enrollment
- Prior exposure to anthracycline
- Patient has concomitant active malignancy that the treating physician or PI feels may interfere with the ability to measure the primary or secondary outcomes
- Patients with a history of curative, surgically treated basal or squamous cell carcinoma or stage 1 melanoma of the skin or in situ carcinoma of the cervix are eligible.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (2 Sites)
- James P. Wilmot Cancer Institute, University of Rochester Medical Center — Rochester, New York
- University of Virginia Cancer Center — Charlottesville, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.